Cytomegalovirus Infection Post-hematopoietic Stem Cell Transplant: Incidence, Risk Factors, and Outcome in an Omani Cohort

Overview

Journal Oman Med J

Specialty General Medicine

Date 2024 Jan 29

PMID 38283210

Authors

Fatma Al Farsi

Khuloud Al Maamari

Fatma Ba Alawi

Murtadha Al-Khabori

David Dennison

Abdullah Al Busaidi

Iman Al Manthari

Affiliations

Soon will be listed here.

Abstract

Objectives: To estimate the incidence, risk factors, and outcome of cytomegalovirus (CMV) infection during the first year following hematopoietic stem cell transplant (HSCT) among Omani patients.

Methods: This retrospective study included allogenic HSCT recipients between January 2006 and December 2018. We investigated the possible factors associated with CMV infection and CMV impact on one-year mortality.

Results: Among 556 recipients of allogenic HSCT, 308 (55.4%) were male, the median age was 12 years, and 366 (65.8%) had benign conditions. One-year after transplants, the prevalence of CMV infection was 59.4%, and that of CMV disease was 1.8%. Multivariate analyses revealed significant relationships between CMV infection and haploidentical transplant ( 0.006), graft versus host disease ( 0.013), myeloablative conditioning ( 0.001), and patient age ≥ 12 years ( < 0.001). CMV infection was associated with an increased risk of one-year mortality ( 0.001). One-year overall mortality was 8.3%.

Conclusions: The incidence of CMV infection in this Omani cohort was comparable with earlier findings, but the disease incidence and overall mortality were lower. Older age, haploidentical transplant, myeloablative conditioning, and graft versus host disease were significantly associated with a higher risk of CMV infection. In addition, CMV infection was associated with an increased risk of overall mortality in the first year post-transplant. Our findings support early initiation of preemptive therapy at low-level CMV viremia.

References

Boeckh M, Leisenring W, Riddell S, Bowden R, Huang M, Myerson D . Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2002; 101(2):407-14. DOI: 10.1182/blood-2002-03-0993. View

Lin H, Han S, Hwang W, Chou C, Chang K, Shi Z . Cytomegalovirus Infection and Treatment in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study from a Single Institution in an Endemic Area. Turk J Haematol. 2016; 34(2):159-166. PMC: 5440868. DOI: 10.4274/tjh.2016.0225. View

Rowe R, Guo D, Lee M, Margossian S, London W, Lehmann L . Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center. Biol Blood Marrow Transplant. 2016; 22(7):1275-1283. PMC: 5491305. DOI: 10.1016/j.bbmt.2016.04.004. View

Ranti J, Perkonoja K, Kauko T, Korhonen R . Clinical and healthcare burden of disease associated with cytomegalovirus in allogeneic hematopoietic stem cell transplantation - A retrospective single-center study. Transpl Infect Dis. 2022; 24(6):e13947. PMC: 10369922. DOI: 10.1111/tid.13947. View

Azevedo L, Pierrotti L, Abdala E, Costa S, Strabelli T, Campos S . Cytomegalovirus infection in transplant recipients. Clinics (Sao Paulo). 2015; 70(7):515-23. PMC: 4496754. DOI: 10.6061/clinics/2015(07)09. View

Nichols W, Price T, Gooley T, Corey L, Boeckh M . Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood. 2003; 101(10):4195-200. DOI: 10.1182/blood-2002-10-3143. View

Bazarbachi A, Labopin M, Ghavamzadeh A, Giebel S, Al-Zahrani H, Ladeb S . Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern Mediterranean (EMBMT) and European (EBMT) centers. Bone Marrow Transplant. 2013; 48(8):1065-9. DOI: 10.1038/bmt.2013.1. View

Sousa H, Boutolleau D, Ribeiro J, Teixeira A, Vaz C, Campilho F . Cytomegalovirus infection in patients who underwent allogeneic hematopoietic stem cell transplantation in Portugal: a five-year retrospective review. Biol Blood Marrow Transplant. 2014; 20(12):1958-67. DOI: 10.1016/j.bbmt.2014.08.010. View

Diaz L, Rosales J, Rosso F, Rosales M, Estacio M, Manzi E . Cytomegalovirus disease in patients with hematopoietic stem cell transplantation, experience over 8 years. Hematol Transfus Cell Ther. 2019; 42(1):18-24. PMC: 7031091. DOI: 10.1016/j.htct.2018.10.004. View

10.

Boeckh M, Nichols W . The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2003; 103(6):2003-8. DOI: 10.1182/blood-2003-10-3616. View

11.

Chemaly R, Ullmann A, Stoelben S, Richard M, Bornhauser M, Groth C . Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014; 370(19):1781-9. DOI: 10.1056/NEJMoa1309533. View

12.

Bhat V, Joshi A, Sarode R, Chavan P . Cytomegalovirus infection in the bone marrow transplant patient. World J Transplant. 2016; 5(4):287-91. PMC: 4689939. DOI: 10.5500/wjt.v5.i4.287. View

13.

Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T . Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for.... Biol Blood Marrow Transplant. 2015; 21(11):2008-16. DOI: 10.1016/j.bbmt.2015.07.019. View

14.

Marty F, Ljungman P, Papanicolaou G, Winston D, Chemaly R, Strasfeld L . Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011; 11(4):284-92. DOI: 10.1016/S1473-3099(11)70024-X. View

15.

Broers A, van Der Holt R, van Esser J, Gratama J, Kuenen-Boumeester V, Lowenberg B . Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood. 2000; 95(7):2240-5. View

16.

Garrido R, Aguado J, Diaz-Pedroche C, Len O, Montejo M, Moreno A . A review of critical periods for opportunistic infection in the new transplantation era. Transplantation. 2006; 82(11):1457-62. DOI: 10.1097/01.tp.0000245676.43979.86. View

17.

Boeckh M, Murphy W, Peggs K . Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. Biol Blood Marrow Transplant. 2014; 21(1):24-9. DOI: 10.1016/j.bbmt.2014.11.002. View

18.

Al-Khabori M, Al-Huneini M . Hematopoietic stem cell transplantation in the Sultanate of Oman. Hematol Oncol Stem Cell Ther. 2017; 10(4):305-307. DOI: 10.1016/j.hemonc.2017.05.024. View

19.

Green M, Leisenring W, Xie H, Mast T, Cui Y, Sandmaier B . Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016; 3(3):e119-27. PMC: 4914379. DOI: 10.1016/S2352-3026(15)00289-6. View